Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice

International Journal of Cancer

Volumn 73, Issue 1, 1997, Pages 156-163

  Vassal, Gilles ^a   Boland, Isabelle ^a   Santos, Alexandre ^a   Bissery, Marie Christine ^b   Terrier Lacombe, Marie José ^a   Morizet, Jackie ^a   Sainte Rose, Christian ^c   Lellouch Tubiana, Arielle ^c   Kalifa, Chantai ^a   Gouyette, Alain ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SANOFI   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG POTENCY; MEDULLOBLASTOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHILD; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MEDULLOBLASTOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030815503     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970926)73:1<156::AID-IJC24>3.0.CO;2-D     Document Type: Article

References (25)

1. ARMAND, J-P., CPT-11: clinical experience in phase I. Semin. Oncol., 23, (Suppl. 3), 27-33 (1996).
2. BARLERO, I., GANDIA, D., ARMAND, J-P., MATHIEU-BOUÉ, A., RE, M., GOUYETTE, A. and CHABOT, G., Simultaneous detection of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid enromatography: application to plasma pharmucokinetic studies in cancer patients. J. Chromatogr. (Biomed.) Appl.), 575, 275-280 (1992).
3. BISSERY, M.C., VRIGNAUD, P., LAVELLE, F. and CHABOT, G.G., Experimental antitumor activity of CPT-11 and pharmacokinetics of the camptothecin analog irinotecan (CPT-11 )in mice. Anti-cancer Drugs, 7, 437-160 (1996).
4. BOOR, R., HUBER, A. and GUTLAHR, P., Etoposide treatment in recurrent modulloblastoma. Neuropediatrics, 25, 39-41 (1994).
5. CHABOT, G.G., ABIGERGES, D., CATIMEL, G., CULINE, S., DE FORNI, M., EXTRA, J.M., MAJHOUBI, M., HERAIT, P., ARMAND, J.P., BUGAT, R., CLAVEL, M. and MARTY, M.E., Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann.Oncol., 6, 14-151 (1995).
6. GENTET, J.C. and 13 OTHERS. Carboplatin and VP16 in medulloblastoma: a phase II study of the French Society of Pediatric Oncology (SFOP). Med. Pediatr. Oncol., 23, 422-427 (1994).
7. GUPTA, E., LESTINGI, T.M., MICK, R., RAMIREZ, J., YOKES, E.E. and RATAIN, M.J., Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 54, 3723-3725 (1994).
8. HERBEN, V.M.M., TEN BOKKEL HUTNINK, W.W. and BEIJNEN, J.H., Clinical pharmacokinetics of topotecan. Clin. Pharmacokinet., 31, 85-102 (1996).
9. HOUGHTON, P.J., CHESCHIRE, P.J., HALLMAN, J.C., BISSERY, M.C., MATHIEU-BOUÉ, A. and HOUGHTON, J.A., Therapeutic activity of the topoisomerase I inhibitor 7-ethy 1-10-(4[I-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res., 53, 2823-2829 (1993).
10. HUGHTON, P.J., CHESCHIRE, P.J., HALLMAN, J.D. 2ND, LUTZ, L., FRIBDMAN, H.S., DANKS, M.K. and HOUGHTON, J.A., Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36, 393-403 (1995).
11. HSIANG, Y.H.,. LIHOU, L.F. and LIU, L.F., Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as u mechanism of cell killing by camptothecin. Cancer Res., 49, 5077-5082 (1989).
12. KALIFA, C., HARTMANN, O., DEMEOCQ, F., VASSAL, G., COUANET, D., TERRIER-LACOMBE, M.J., VALTEAU, D., BRUGÉRES, L. and LEMERLE, J., High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: u phase II study. Bone Marrow Transplant., 9, 227-233 (1992).
13. KANEDA, N., NAGATA, H., FURUTA, T. and YOKOKURA, T., Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res., 50, 1713-1720 (1990).
14. KAWATO, Y. FURUTA, T., AONUMA, M., YOKOKURA, T. and MATSUMOTO, K., Antitumor activity of a camptothecin derivative, CPT-11. against human tumour xenografts in nude mice. Cancer Chenmther. Phanmtcol., 28, 192-198 (1991).
15. KOMURO, H., Li, P., TSUCHIDA, Y., YOKOMORI, K., NAKAJIMA, K., AOYAMA, T., KANEDO, M. and KANEDA, N., Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on u highly malignant xeno-transplanted neuroblastoma. Med. Pediatr. Oncol., 23, 487-492 (1994).
16. LAVELLE, F., BISSERY, M.C., ANDRÉ, S., ROQUET, F. and RIOU, J.F., Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin. Oncol., 23 (Suppl, 3). 11-20 (1996).
17. MOGRABI, A., FUCHS, H. and BROWN. M., Cyclophosphamide in combination with sagramostin in the treatment of recurrent medulloblastoma. Med. Pediatr. Oncol., 25, 190-196 (1995).
18. ROTHENBERG, M.L., CPT-11: an original spectrum of clinical activity. Semin. Oncol., 23 (Suppl. 3), 21-26 (1996).
19. ROWINSKY, E.K., GROCHOW, L., ETTINGER, D.S., SARTORIUS, S.E., LUBEJKO, B.C., CHAN, T.L., ROCK, M.K. and DONEHOWER, R.C., Phase I and pharmacological study of the novel topoisornerase I inhibitor 7-ethyl-10-(4[ l-piperidino]-l-piperidino)-carbonyloxy-camptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res., 54, 427-436 (1994).
20. SLEVIN, M.L., CLARK, P.I. JOEL, S.P., MALIK, S., OSBORNE, R.J., GREGORY, W., LOWE, D.G., REZNEK, R.H. and WRIGLEY, G., A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J. clin. Oncol., 7, 1333-1340 (1989).
21. THOMPSON, J., ZAMBONI, W.C., CHESCHIRE, P.J., LUTZ, L., Luo, X., Li, Y., HOUGHTON, J.A., STEWART, C.F. and HOUGHTON, P.J., Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin. Cancer Res., 3, 423-431 (1997).
22. TSURUO, T., MATSUZAKI, T., MATSUSHITA, M., SAITO, H. and YOKOKURA, T., Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol., 21, 71-74 (1988).
23. VASSAL, G., SANTOS, A., PEIN, F., FRAPPAZ, D., MIGNARD, D. and Doz, F., Pharmacokinetics of irinotecan (CPT-11) and its metabolites in children. Proc. Amer. Ass. Cancer Res., 38, 75 (1997).
24. VASSAL. G., TERRIER-LACOMBE, M.J., BISSERY, M.C., VENUAT, A.M., GYERGYAY, F., BÉNARD, J., MORIZET, J., BOLAND, I., ARDOUIN, P., BRESSACDE-PAILLERETS, B. and GOUYETTE, A., Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br. J. Cancer. 74, 537-545 (1996a).
25. VASSAL, G., TERRIER-LACOMBE, M.J., LELLOUCH-TUBIANA, A., VALERY, C.A., SAINTE-ROSE, C., MORIZET, J., ARDOUIN, P., RIOU, G., KALIFA, C. and GOUYETTE, A., Tumorigenicity of cerebellar primitive neuro-ectodermal tumors in athymic mice correlates with poor prognosis in children. Int. J. Cancer (Pred. Oncol.), 69, 146-151 (1966b).